JP2009541373A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541373A5
JP2009541373A5 JP2009516901A JP2009516901A JP2009541373A5 JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5 JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5
Authority
JP
Japan
Prior art keywords
vaccine
adjuvant
peptide
protein
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009516901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541373A (ja
JP5165681B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2007/000312 external-priority patent/WO2008000261A2/en
Publication of JP2009541373A publication Critical patent/JP2009541373A/ja
Publication of JP2009541373A5 publication Critical patent/JP2009541373A5/ja
Application granted granted Critical
Publication of JP5165681B2 publication Critical patent/JP5165681B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009516901A 2006-06-28 2007-06-26 タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大 Expired - Fee Related JP5165681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600861 2006-06-28
DKPA200600861 2006-06-28
PCT/DK2007/000312 WO2008000261A2 (en) 2006-06-28 2007-06-26 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Publications (3)

Publication Number Publication Date
JP2009541373A JP2009541373A (ja) 2009-11-26
JP2009541373A5 true JP2009541373A5 (enExample) 2010-07-29
JP5165681B2 JP5165681B2 (ja) 2013-03-21

Family

ID=38845996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516901A Expired - Fee Related JP5165681B2 (ja) 2006-06-28 2007-06-26 タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大

Country Status (11)

Country Link
US (2) US8105614B2 (enExample)
EP (3) EP2402023A1 (enExample)
JP (1) JP5165681B2 (enExample)
KR (1) KR20090024292A (enExample)
AU (1) AU2007264205B2 (enExample)
BR (1) BRPI0713978A2 (enExample)
CA (1) CA2654271A1 (enExample)
DK (1) DK2040745T3 (enExample)
ES (1) ES2400531T3 (enExample)
RU (1) RU2490024C2 (enExample)
WO (1) WO2008000261A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941545D1 (de) 1998-11-04 2009-11-26 Isis Innovation Tuberkulose diagnose test
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
MX2009013008A (es) * 2007-05-31 2010-06-09 Vacunas para la influenza.
BRPI0811796A2 (pt) * 2007-06-26 2020-04-28 Statens Serum Institut Uso de um monomicolil glicerol (mmg) ou de homólogos ou análogos sintéticos e versões modificadas, adjuvante ou imunomodulador, homólogo ou análogo de mmg sintético ou uma versão modificada, vacina e sistema de aplicação
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
JP5715051B2 (ja) * 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2614802T3 (es) * 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
TR201903223T4 (tr) * 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
US20110104195A1 (en) * 2009-11-05 2011-05-05 Joao Aguiar Plasmodium falciparum sporozoite and liver stage antigens
US9107875B2 (en) * 2009-11-18 2015-08-18 Auburn University Low antigen-dose immunization for maximizing T-helper cell 1 (Th1) immunity against a pathogen
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
DK3079716T3 (da) * 2013-12-13 2019-08-19 Us Health Multiepitop-tarp-peptidvaccine og anvendelser deraf.
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN117064854A (zh) * 2023-08-14 2023-11-17 广州谦毅生物医药有限公司 一种卡瓦脂质体的制备技术

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
EP0979867A3 (en) * 1993-11-04 2007-06-13 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
CZ302870B6 (cs) * 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
WO2006002642A2 (en) 2004-07-07 2006-01-12 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
FR2873467A1 (fr) 2004-07-26 2006-01-27 Proton World Internatinal Nv Enregistrement d'une cle dans un circuit integre
DK1991266T3 (da) * 2006-01-26 2013-08-26 Zoetis P Llc Nye glycolipid-adjuvant-sammensætninger
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides

Similar Documents

Publication Publication Date Title
JP2009541373A5 (enExample)
Kaur et al. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects
US12070498B2 (en) Conjugate vaccine targeting a disease-causing biological protein
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
CN103747797B (zh) 脂质体制剂
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
EP2200638B1 (en) Compositions for the transfection of cells
RU2009102389A (ru) Расширение спектра клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
JP2011512123A5 (enExample)
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
JP2011518179A5 (enExample)
JP2003531128A (ja) 修飾ペプチドを含む医薬調製物
JP6158097B2 (ja) 炎症を抑制するためのペプチド
JP5766894B2 (ja) ワクチン増強剤としてのαチモシンペプチド
CN102088992B (zh) 肽基二酰基甘油酯
Simerska et al. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines
JP7050807B2 (ja) 新規ペプチドベースのｐｃｓｋ９ワクチン
WO2012147805A1 (ja) 脳移行性機能性核酸及びその利用
JP2008531463A5 (enExample)
KR20090009839A (ko) 면역조절 올리고펩티드
CN101336110B (zh) 预防或治疗肝损伤的肽及其衍生物及其应用
RU2003110420A (ru) Дифференцирование gnrh-i и gnrh-ii
JPWO2000051634A1 (ja) 脂肪酸を構成成分とするワクチン製剤
CN102178926A (zh) 预防或治疗肝损伤的肽
CN119818665A (zh) 新型发热伴血小板减少综合征病毒疫苗